Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model
Main Authors: | R. Merkx, A. Kip, G.M. Franssen, E. Oosterwijk, A. Morgenstern, F. Bruchertseifer, M. Wheatcroft, E. Yan, M. Rijpkema, S. Heskamp, P.F.A. Mulders |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-07-01
|
Series: | European Urology Open Science |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168320335801 |
Similar Items
-
Evaluation of Actinium-225 Labeled Minigastrin Analogue [<sup>225</sup>Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
by: Yun Qin, et al.
Published: (2020-11-01) -
Development of [<sup>225</sup>Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
by: Eline L. Hooijman, et al.
Published: (2021-05-01) -
Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report
by: Letjie C. Maserumule, et al.
Published: (2021-03-01) -
Ac-EAZY! Towards GMP-Compliant Module Syntheses of <sup>225</sup>Ac-Labeled Peptides for Clinical Application
by: Marc Pretze, et al.
Published: (2021-07-01) -
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
by: Franziska Graf, et al.
Published: (2014-01-01)